Mercados españoles abiertos en 6 hrs 20 min

Evotec SE (EVO)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
5,27-0,10 (-1,86%)
Al cierre: 04:00PM EDT
5,28 +0,01 (+0,19%)
Después del cierre: 05:09PM EDT

Evotec SE

Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com

Sector(es)Healthcare
SectorDrug Manufacturers - Specialty & Generic
Empleados a tiempo completo5061

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Mario Polywka DPHIL, Ph.D.CEO & Chairman of the Management Board & Member of the Supervisory BoardN/AN/A1963
Dr. Cord Dohrmann Ph.D.Chief Scientific Officer & Member of Management Board866,07kN/A1964
Dr. Craig Johnstone Ph.D.COO & Member of Management Board766,97kN/A1970
Dr. Matthias Evers Ph.D.Chief Business Officer & Member of Management Board685,1kN/A1973
Ms. Laetitia RouxelCFO & Member of Management BoardN/AN/A1975
Ms. Anja BoslerPrincipal Accounting Officer and Senior Vice President of Group AccountingN/AN/AN/A
Mr. Volker BraunExecutive VP and Head of Global Investor Relations & ESGN/AN/AN/A
Dr. Christian DargelEVP Global Head of Legal & ComplianceN/AN/AN/A
Gabriele HansenSenior VP & Head of Global Corporate Communications & MarketingN/AN/AN/A
Dr. Ian M. HunneyballSenior Vice President of Programme Management & Clinical Operations124,95kN/A1950
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Gobierno corporativo

El ISS Governance QualityScore de Evotec SE, a día 1 de mayo de 2024, es 6. Las puntuaciones base son Auditoría: 4; Tablero: 4; Derechos de los accionistas: 1; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.